Merck Serono is partnering with Intrexon Corporation to develop Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The companies announced today that they have entered an exclusive strategic collaboration and license agreement for CAR-T cancer drugs, advancing Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s …
Tag Archives: Merck Serono
March, 2015
-
10 March
Merck Serono Partners with Illumina to Develop a University NGS-Based Oncology Diagnostic
Illumina announced that it is partnering with Merck Serono to develop a universal oncology diagnostic that uses next-generation sequencing (NGS). The companies will collaborate to develop a universal NGS-based oncology diagnostic for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine. The …